TALIS BIOMEDICAL CORP's ticker is TLIS and the CUSIP is 87424L108. A total of 42 filers reported holding TALIS BIOMEDICAL CORP in Q3 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $43,902 | +54777.5% | 91,463 | -44.1% | 0.00% | – |
| Q1 2023 | $80 | +63.3% | 163,663 | +47.4% | 0.00% | – |
| Q4 2022 | $49 | -99.9% | 111,036 | -14.2% | 0.00% | – |
| Q3 2022 | $88,000 | -46.3% | 129,372 | -35.9% | 0.00% | – |
| Q2 2022 | $164,000 | +4.5% | 201,913 | +1320.0% | 0.00% | – |
| Q2 2021 | $157,000 | – | 14,219 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenlight Capital | 1,569,300 | $6,293,000 | 0.36% |
| ArrowMark Colorado Holdings LLC | 4,915,239 | $19,710,000 | 0.16% |
| Baker Brothers Advisors | 7,624,835 | $30,576,000 | 0.15% |
| Golden State Equity Partners | 22,133 | $89,000 | 0.04% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 188,269 | $755,000 | 0.02% |
| PDT Partners, LLC | 34,890 | $140,000 | 0.01% |
| PERSONAL CFO SOLUTIONS, LLC | 10,000 | $40,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 32,500 | $130,000 | 0.00% |
| Qube Research & Technologies Ltd | 59,161 | $237,000 | 0.00% |
| TWO SIGMA INVESTMENTS, LP | 78,628 | $315,000 | 0.00% |